WHO vaccine-preventable diseases: monitoring system. 2018 global summary

Last updated 15-Jul-2018 (data as of 15-Jul-2018)
Next overall update Winter 2018
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 37'2701 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 38'4131 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2017  2016  2015  2014  2013  2000  1990  1980 
Total population 8'322  8'192  8'065  7'941  7'821  6'014  4'500  3'745 
Births 166  166  167  166  165  127  100  93 
Surviving infants 165  166  166  166  165  127  99  92 
Pop. less than 5 years 842  841  830  819  804  614  483  458 
Pop. less than 15 years 2'319  2'286  2'247  2'208  2'166  1'689  1'406  1'237 
Female 15-49 years 1'932  1'906  1'883  1'859  1'837  1'503  1'097  874 

Number of reported cases

(Click for retrospective incidence data for Israel)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  42  80  50  36  230  215 
Mumps
ChartChart
  353  51  47  140  51  48 
Pertussis
ChartChart
  467  1'143  5'338  1'509  1'394  452  155  19 
Polio*
ChartChart
  11 
Rubella
ChartChart
  54 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Israel)
Vaccine year result method % card seen                                                
BCG          75 
DTP1          99  94  95  95  96  96  97  94 
DTP3          98  94  95  95  96  96  93  84 
DTP4          95  95  96  94 
IPV1          99 
HepB_BD          95  96  97  97  99* 
HepB3          97  95  96  97  97  97 
Hib3          98  94  95  95  96  94 
JapEnc         
MCV1          98  97  98  97  98  97  91  81 
MCV2          96  97  97  96  95 
MenA         
PCV1          99 
PCV2          97 
PCV3          94  93  94  94  94 
Pol3          98  94  95  95  94  92  93  85 
Rota1          93 
RotaC          81  81  80  81  80 
RCV1          98  97  98  97  98 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid July 2019

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Israel)
BCG
  75 
DTP1
ChartChart
  99  94  95  95  96  95  97  94 
DTP3
ChartChart
  98  94  95  95  96  93  93  84 
HepB3
ChartChart
  97  95  96  97  97  98 
HepB_BD
ChartChart
  95  95  96  97  97  96 
Hib3
ChartChart
  98  94  95  95  96  93 
MCV1
ChartChart
  98  97  98  97  98  95  91  81 
MCV2
ChartChart
  96  97  97  96  95 
PCV3
ChartChart
  94  93  94  94  94 
Pol3
  98  94  95  95  96  93  93  85 
RCV1
ChartChart
  98  97  98  97  98  95 
RotaC
ChartChart
  81  81  80  81  80 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 15  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2017 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG Yes risk groups
DT 2, 4, 6, 12 months; Yes if Pertussis contraindicated
DTaP 2, 4, 6, 12 months; Yes catch up vaccine up to 6 y.
DTaPHibIPV 2, 4, 6, 12 months; Yes
HepA_Adult Yes risk groups and travellers
HepA_Pediatric 18, 24 months; Yes
HepB_Adult Yes risk groups and travellers
HepB_Pediatric birth; 1, 6 months; Yes and risk groups
Hib Yes risk groups and catch-up
HPV 13 years; +6 months; Yes girls and boys
Influenza_Adult >=65 years; Yes and adults with chronic illness, pregnant women, health care workers, other risk groups
Influenza_Pediatric 6 months-18 years; Yes and children with chronic illness
IPV Yes risk groups, catch-up
JE_Inactd Yes travellers
MenACWY-135 conj Yes risk groups
MenACWY-135 ps Yes risk groups
MMR Yes risk groups
MMRV 12 months; 6 years; Yes risk groups
OPV 6, 18 months; Yes
Pneumo_conj 2, 4, 12 months; Yes and at 6 months for risk groups
Pneumo_ps >=65 years; Yes risk groups
Rotavirus 2, 4, 6 months; Yes
TBE Yes travellers (paediatric and adult)
Td Yes every ten years to adult population and for tetanus prophilaxis in wound management
Tdap 13 years; Yes and adults in risk group and pregnant women
TdaPIPV 7 years; Yes and at-risk adults
TT tetanus prophilaxis in wound management
Typhoid Yes travellers
TyphoidHepA Yes travellers
Varicella Yes catch-up and risk groups
YF Yes travellers
Zoster >=60 years; Yes

Immunizaton indicators

Indicator Expected answer 2017  2016  2015  2014  2013  2012  2011 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2018-2028        10 years 
Nº of districts with microplans that include activities to raise immunization coverage number 15  15  15  15  15  15  15 

System performance

Total Nº districts in country number 15  15      15  15  15 
Nº districts with DTP3 coverage >=80% number 15  15  15  15  15  15  15 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100      100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 15  15  15  12  15  15 
% of districts with MCV1 coverage >=95% From 0 to 100% 100  100      100  100 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 100  100  100  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2018 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2018, data for 2016
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.